Bruton Tyrosine Kinase (BTK) Inhibitors in Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia : Episode 8

BTK Inhibitors in MCL and CLL

March 10, 2023

Article

EP: 1.Dr. Kumar on Treatment Options for Patients Who Progress on a BTK Inhibitor in MCL

EP: 2.Dr. Lunning on Trials Evaluating BTK Inhibitors in CLL

EP: 3.Dr. Maddocks on the Investigation of Noncovalent BTK Inhibitors in MCL

EP: 4.Dr. Danilov on the Future of BTK Inhibitors in CLL

EP: 5.The Role of Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

EP: 6.Dr. Owen on Choosing Between BTK Inhibitors in CLL

EP: 7.Dr. Torka on the Role of Pirtobrutinib in R/R MCL

EP: 8.BTK Inhibitors in MCL and CLL

EP: 9.Dr. Phillips on BTK Inhibitor Selection in MCL

Related Videos

Tycel Phillips, MD, MPH

Pallawi Torka, MD

Carolyn Owen, MD, FRCPC

Alexey V. Danilov, MD, PhD

Kami J. Maddocks, MD

Matthew A. Lunning, DO, FACP

Anita Kumar, MD

Sarah Sammons, MD

Laura Spring, MD

Related Content

An Evolving Treatment Paradigm: ADCs in Non–Small Cell Lung Cancer

An Evolving Treatment Paradigm: ADCs in Non–Small Cell Lung Cancer

April 11th 2024

Expanding Horizons: Antibody-Drug Conjugates in Non–Small Cell Lung Cancer

Expanding Horizons: Antibody-Drug Conjugates in Non–Small Cell Lung Cancer

April 21st 2023

Clinical Decision Making in Advanced NSCLC without Actionable Mutations

Clinical Decision Making in Advanced NSCLC without Actionable Mutations

April 21st 2023

Where Do ADCs Fit Into the Treatment Paradigm for Patients With NSCLC?

Where Do ADCs Fit Into the Treatment Paradigm for Patients With NSCLC?

January 25th 2023

Clinical Case Scenarios: Approaches to Treatment Decisions in Non-Small Cell Lung Cancer

Clinical Case Scenarios: Approaches to Treatment Decisions in Non-Small Cell Lung Cancer

January 25th 2023

$Advances in the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma$

Advances in the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

December 22nd 2022

Related Content

An Evolving Treatment Paradigm: ADCs in Non–Small Cell Lung Cancer

An Evolving Treatment Paradigm: ADCs in Non–Small Cell Lung Cancer

April 11th 2024

Expanding Horizons: Antibody-Drug Conjugates in Non–Small Cell Lung Cancer

Expanding Horizons: Antibody-Drug Conjugates in Non–Small Cell Lung Cancer

April 21st 2023

Clinical Decision Making in Advanced NSCLC without Actionable Mutations

Clinical Decision Making in Advanced NSCLC without Actionable Mutations

April 21st 2023

Where Do ADCs Fit Into the Treatment Paradigm for Patients With NSCLC?

Where Do ADCs Fit Into the Treatment Paradigm for Patients With NSCLC?

January 25th 2023

Clinical Case Scenarios: Approaches to Treatment Decisions in Non-Small Cell Lung Cancer

Clinical Case Scenarios: Approaches to Treatment Decisions in Non-Small Cell Lung Cancer

January 25th 2023

$Advances in the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma$

Advances in the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

December 22nd 2022

Latest Conference Coverage

Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer

As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority

Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD

Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.